Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 4;9(3):618. doi: 10.3390/cells9030618

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The future of CRC therapy: combinatorial agents. The current status of the use of inhibitor therapy (ICI) in the treatment of CRC has shown promising results, despite the lack of a complete response in dMMR-MSI-H tumors, and no response in pMMR-MSI-L. This obstacle has paved the way for insight and research into plausible combinatorial agents that can overcome this scientific impediment. (A) ICI in combination with AMG 510, a KRAS (G12C) inhibitor, or (B) therapeutic cancer vaccines, or (C) adoptive T cell therapy, or (D) TNF and TGFβ inhibitors may serve as the next candidates for combinatorial therapy with ICI.